Tick anticoagulant peptide

Drug Profile

Tick anticoagulant peptide

Latest Information Update: 08 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Peptides
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Reperfusion injury; Thrombosis

Most Recent Events

  • 10 Dec 1997 Preclinical development for Reperfusion injury in South Africa (Unknown route)
  • 10 Dec 1997 A study has been added to the Ischaemic Heart Disease and Thromboses pharmacodynamics sections
  • 02 Oct 1996 An animal study has been added to the Thromboses pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top